India’s Mid-Scale Hotel Market Set for Rapid Growth, With 30 percent of Brands Planning Global Expansion

Bengaluru, Jan 28: India’s mid-scale hotel segment is witnessing significant growth, with the market expanding at a 13% CAGR and poised to reach USD 6.3 billion by 2030, up from USD 3.75 billion in 2023. A new white paper by Hotelogix, a leading global provider of cloud-based hospitality solutions, highlights key trends shaping the sector, including consolidation, international expansion, technology adoption, and IPO momentum.

Titled “India’s Thriving Domestic Mid-Scale Hotel Brands – Redefining the Industry with Consolidation and Collaboration, International Expansion, and Technology Adoption”, the white paper was released following the 2nd edition of Hotelogix & AxisRooms Connect, the only industry event dedicated exclusively to domestic mid-scale hotel brands.

Consolidation and Collaboration
The report predicts that by 2030, large hotel brands — both Indian and international — will control 75%-80% of branded mid-scale rooms, driven by acquisitions and partnerships with local 3-star and budget-plus properties.

“Consolidation will gather pace. More Indian mid-segment brands will sign up with large domestic and global chains. It will help both stakeholders stay relevant in this competitive industry,” said Aryavir Kumar, Managing Director, The Clarks Hotels & Resorts.

International Expansion

Since 2020, 15-20 domestic mid-scale brands have ventured abroad, targeting markets such as the UAE, Nepal, and East Africa. By 2030, around 30% of India’s mid-scale hotel brands are expected to expand internationally, serving the growing base of 30 million outbound Indian travelers. Brands such as Lemon Tree and Royal Orchid Hotels are already operational in Dubai and Sri Lanka, while others like Elivaas are exploring franchise-led expansion.

“By 2030, about 30% of India’s mid-scale hotel brands will cross borders, transforming themselves into global ambassadors of authentic Indian hospitality,” said Anant Apurv Kumar, Founder, Brij Hotels.

Technology Adoption

Digital adoption is accelerating, with one in three multi-property mid-scale brands already using cloud-based platforms. By 2030, adoption is projected to reach 60%-70%, enabling centralised control, scalability, and AI-driven operational efficiencies.

“Affordable, modern cloud solutions now allow smaller brands like ours to digitise operations, making technology adoption much more accessible,” said Jaideep Ahuja, MD & CEO, Ahuja Residency.

IPO Momentum

Currently, around 5% of domestic mid-scale brands are publicly listed. The white paper projects that 6%-8% more brands will pursue Initial Public Offerings (IPOs) over the next two years.

“Growth-focused brands with asset-light models will continue to attract capital, reflecting buoyant investment across the hospitality sector,” said Arjun Baljee, President, Royal Orchid Hotels Ltd.

“India’s mid-scale hotel brands, representing roughly 60% of the country’s branded rooms, are leveraging local insights and agile business models to capture new demand in emerging cities,” added Aditya Sanghi, CEO, Hotelogix.

The white paper underscores that consolidation, international expansion, technology adoption, and capital market participation will define the next phase of growth for India’s mid-scale hotel industry.

Rajendra Joshi Elevated to Associate General Manager, Pre-opening Operations at Sayaji Hotels Ltd

Mumbai, India, Jan 28:  Sayaji Hotels Ltd proudly announces the elevation of Rajendra Joshi to the role of Associate General Manager – Pre-opening Operations, effective from January 2026. In this expanded leadership position, Mr. Joshi will play a pivotal role in driving operational excellence and steering strategic property launches as the hospitality group continues its rapid expansion across India.

With nearly two decades of rich experience in the hospitality industry, Rajendra Joshi brings a deep understanding of hotel operations, food and beverage services, guest experience optimisation and team development. Prior to his current role, he held senior management and general manager positions at several respected hospitality brands, honing his ability to deliver high service quality and operational effectiveness across diverse market segments.

Since stepping into his leadership role at Sayaji Hotels Ltd, Rajendra Joshi has been central to the organisation’s strategic expansion initiatives. He has overseen key operational milestones and contributed to new property launches, positioning the brand to serve emerging markets with a blend of contemporary comfort and personalised hospitality.

On his elevation, Mr. Joshi commented,

“I am honoured to take on this expanded responsibility at Sayaji Hotels Ltd. As we grow our footprint across India, my focus remains on delivering memorable guest experiences while nurturing a team culture rooted in excellence and collaboration.” 

Mr. Joshi’s career highlights include significant leadership roles at prominent properties, including The Fern Residency, Aurangabad and U Tropicana, Alibaug, where he was instrumental in enhancing guest satisfaction, streamlining operations, and driving business growth. His expertise spans pre-opening coordination, resource planning, talent engagement and fostering a culture of continuous improvement.

TV Industry Urges Focused Budget Support to Boost Domestic Manufacturing and Exports

As the Union Budget approaches, the television manufacturing industry hopes for a focused policy support that reflects the reality of TVs no longer being a luxury product, but an integral part of the Indian household. With the Indian TV industry valued at nearly USD 15 billion, it plays a significant role in domestic manufacturing, employment generation, and value addition under the Make in India vision.

Despite this scale, the sector has not received the same policy priority as categories like mobile phones. One long-standing expectation that has remained unaddressed across multiple Union Budgets is the introduction of a dedicated PLI framework for television manufacturing. Such a move could significantly accelerate localisation, strengthen domestic value chains, and improve global competitiveness.

While earlier GST rationalisation provided some relief, persistent challenges such as limited display fab availability, volatility in memory prices, rupee depreciation and ongoing semiconductor supply constraints have diluted its impact. Although the government has taken important steps to build a domestic ecosystem for critical components, semiconductors, and display fabs, a stronger and more coordinated ecosystem push is needed to truly encourage domestic manufacturing. In the interim, the industry hopes this Budget considers temporary duty relief and targeted support for critical components to improve supply stability, cost competitiveness, and support the long-term growth of India’s TV manufacturing industry. Additionally, export-focused measures such as duty drawbacks, logistics support, and rationalised trade barriers will be critical to enhance competitiveness, enable scale beyond the domestic market, and strengthen India’s position in global electronics and television exports.

Akums Strengthens Presence in Regulated Markets with EU GMP Approvals for 2 Haridwar Plants

New Delhi, Jan 28: Akums Drugs & Pharmaceuticals Ltd., a leading Contract Development and Manufacturing Organization (CDMO), has achieved a significant regulatory milestone with the renewal of European Union Good Manufacturing Practice (EU GMP) certification for its Plant 1 facility and the grant of EU GMP certification for its Plant 2 facility, both located in SIDCUL, Haridwar. The certifications were awarded following recent inspections conducted by the European Medicines Agency (EMA).

The EU-GMP audits comprehensively assessed Akums’ manufacturing operations, quality management systems, documentation practices, and compliance with EU GMP guidelines across both facilities. Based on the satisfactory inspection outcomes, the Drug agency renewed the EU GMP approval for Plant 1 and granted fresh certification for Plant 2.

With both facilities now operating under EU GMP norms, Akums is well positioned to expand its presence across Europe and other highly regulated geographies, supporting customers with a broader portfolio of high-quality oral formulations.

Akums Manufacturing Plant 1, located in SIDCUL, Haridwar, continues to serve as a key manufacturing hub for oral solid dosage forms. Under the renewed EU GMP certification, the approved scope includes tablets, hard gelatin capsules, and powder sachets. The facility is supported by advanced automation, precision manufacturing technologies, and robust quality systems designed to ensure consistent compliance with stringent international regulatory requirements.

Another Manufacturing Plant (Plant 2) which received EUGMP Certification, The newly granted EU GMP certification covers oral liquid dosage forms, including liquids, syrups, and suspensions. The facility features modern infrastructure and comprehensive quality control systems to support reliable and scalable manufacturing for regulated markets.

Commenting on the development, Mr. Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., said:

“This milestone goes beyond regulatory approval—it reflects years of focused investment in quality systems, infrastructure, and people. The renewal of EU GMP certification for Plant 1 and the new certification for Plant 2 strengthen our ability to serve regulated markets with confidence. As an organisation supplying a significant share of India’s domestic pharmaceutical needs and exporting to over 65 countries, this achievement supports our long-term partnerships and sustained global growth.”

Mr. Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., added:

“EU GMP is amongst the most rigorous global manufacturing standards, and achieving certification across two facilities simultaneously underscores the maturity of our compliance and operational capabilities. This enables our partners to rely on Akums for consistent quality across both oral solid and oral liquid dosage forms, while enhancing our access to Europe and other regulated markets. Our focus remains on building a globally respected manufacturing platform that delivers safe, effective, and affordable medicines worldwide.”

EU GMP certification is widely recognized as one of the highest benchmarks in pharmaceutical manufacturing and is accepted by regulatory authorities across Europe and several other regulated regions. The certification enables Akums to supply products manufactured at both Haridwar facilities to these markets and supports the company’s continued international expansion.